Compare iShares iBoxx $ High Yield Corporate Bond ETF (HYG) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares iBoxx $ High Yield Corporate Bond ETF vs Natera Inc. Common Stock — how do they compare? iShares iBoxx $ High Yield Corporate Bond ETF trades at $76.76 (market cap $17.41B), while Natera Inc. Common Stock trades at $393.27 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 3.3× iShares iBoxx $ High Yield Corporate Bond ETF's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, iShares iBoxx $ High Yield Corporate Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares iBoxx $ High Yield Corporate Bond ETF for 61 Days and Natera Inc. Common Stock for 0 Days on average.
| HYG | NTRA | |
|---|---|---|
Market Cap | $17.41B | $57.03B |
Volume | 63,579,674 | 1,131,157 |
Sector | Fixed Income | Health |
52-Week High | $81.28 | $425.64 |
52-Week Low | $76.81 | $179.42 |
Typical Hold Time | 61 Days | 0 Days |
Enterprise Value | — | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HYG trades at $77.09, down 0.26% amid a bearish technical signal with moving averages indicating selling pressure. The ETF shows neutral oscillator readings with mixed RSI signals. Recent corporate actions include dividend payments scheduled for 2026. The broader bond market faces pressure from rising Treasury yields, with the 10-year yield hitting levels not seen since 2007 according to MarketBeat on September 30, 2026.
The outlook remains cautious as high yield corporate bonds face headwinds from rising interest rates and inflationary pressures. Investment opportunities exist for income-focused investors through scheduled dividends, but risks include continued bond market volatility and economic uncertainty. HYG's performance will be closely tied to Federal Reserve policy and corporate credit conditions.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares iBoxx $ High Yield Corporate Bond ETF
HYG is the world's largest high-yield bond ETF, tracking the Markit iBoxx USD Liquid High Yield Index. It provides liquid exposure to non-investment grade corporate debt, with 2026 top holdings including Cloud Software Group and Medline.
Read more on HYG →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
